Sandoz Boosts Biosimilar Production with New Facility in Slovenia

Sandoz Group AG has announced a significant investment in a new drug substance facility in Ljubljana, Slovenia, aimed at expanding its biosimilar manufacturing capacity. The investment, valued at approximately USD 300 million, incorporates disposable fed-batch technology. This will enhance Sandoz's ability to produce low- to medium-volume biosimilars, complementing existing high-volume capabilities. Expected to be operational by 2029, the facility will increase the company's manufacturing capacity by 8,000 litres.

This facility will also support the company's Bio100 initiative, which focuses on capturing a substantial market share in the biosimilar sector. The new facility is strategically located next to Sandoz's biosimilar development centre, facilitating technology transfers and speeding up production scale-ups. This effort underscores Sandoz's commitment to enhancing flexible manufacturing and maintaining its leadership in the biosimilar market.